The Miller Lab The Miller Lab The Miller Lab
  • Our Approach
  • Meet The Team
  • Publications
  • Presentations
  • Posts
  • Software
  • Funding
  • Slides
  • Donate
2026
University of Louisville
CSCC
Grand Rounds
In this session, Dr. Miller reviews the evolving role of frontline immunotherapy with response-guided subsequent treatment in advanced CSCC. The talk focuses on how early treatment response can inform downstream therapeutic decisions, with an emphasis on optimizing outcomes while minimizing unnecessary toxicity.
Author

David M. Miller

Published

April 21, 2026

University of Louisville · Resident Lecture

Frontline Immunotherapy With Response-guided Subsequent Treatment

A Bayesian Causal Analysis of Dose Intensity, Early Benefit and Treatment De-escalation

FIRST Squamous Cell Carcinoma Immunotherapy
PresenterDavid M. Miller, MD, PhD
DateApril 21, 2026
LocationLouisville, Kentucky
FormatGrand Rounds Resident Lecture

Event

University of Louisville Division of Dermatology Grand Rounds Resident Lecture

Overview

In this session, Dr. Miller reviews the evolving role of frontline immunotherapy with response-guided subsequent treatment in advanced CSCC. The talk focuses on how early treatment response can inform downstream therapeutic decisions, with an emphasis on optimizing outcomes while minimizing unnecessary toxicity.

Learning objectives

By the end of this session, participants will be able to:

  • Describe the rationale for frontline immunotherapy strategies in advanced CSCC
  • Explain the concept of response-guided treatment adaptation and its clinical implications
  • Identify opportunities to individualize therapy to balance efficacy and toxicity
This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement.